MCID: PYD001
MIFTS: 55

Pyoderma Gangrenosum

Categories: Rare diseases, Skin diseases, Bone diseases

Aliases & Classifications for Pyoderma Gangrenosum

MalaCards integrated aliases for Pyoderma Gangrenosum:

Name: Pyoderma Gangrenosum 12 76 53 59 55 44 15 73

Characteristics:

Orphanet epidemiological data:

59
pyoderma gangrenosum
Prevalence: 1-9/100000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/1000000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:8553
ICD10 33 L88
ICD9CM 35 686.01
MeSH 44 D017511
SNOMED-CT 68 74578003
Orphanet 59 ORPHA48104
MESH via Orphanet 45 D017511
UMLS via Orphanet 74 C0085652
ICD10 via Orphanet 34 L88
UMLS 73 C0085652

Summaries for Pyoderma Gangrenosum

NIH Rare Diseases : 53 Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. Lesions may occur either in the absence of any apparent underlying disorder or in association with other diseases, such as ulcerative colitis, Crohn's disease, polyarthritis (an inflammation of several joints together), gammopathy, vasculitis, leukemia, and other conditions. Each year in the United States, pyoderma gangrenosum occurs in about 1 person per 100,000 people. Pyoderma gangrenosum belongs to a group of autoinflammatory skin diseases called neutrophilic dermatoses. Neutrophils are a type of white blood cell or leukocyte which form an early line of defense against bacterial infections. Ulcerations associated with pyoderma gangrenosum may occur after trauma or injury to the skin, a process called pathergy. Treatment involves wound care and the use of anti-inflammatory agents, including antibiotics, corticosteroids, immunosuppressants, and biologics. 

MalaCards based summary : Pyoderma Gangrenosum is related to ileocolitis and hidradenitis. An important gene associated with Pyoderma Gangrenosum is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Infliximab and Gastrointestinal Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and lung, and related phenotypes are atrophic scars and rheumatoid arthritis

Wikipedia : 76 Pyoderma gangrenosum is a condition that causes tissue to become necrotic, causing deep ulcers that... more...

Related Diseases for Pyoderma Gangrenosum

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 280)
# Related Disease Score Top Affiliating Genes
1 ileocolitis 32.7 NOD2 TNF
2 hidradenitis 31.3 NOD2 TNF
3 hidradenitis suppurativa 31.2 NOD2 TNF
4 colitis 31.0 CXCL8 NOD2 TNF
5 ulcerative colitis 31.0 CXCL8 NOD2 TNF
6 scleritis 30.8 ITGB2 TNF
7 sapho syndrome 30.7 CXCL8 NOD2
8 fasciitis 30.7 CXCL8 TNF
9 vasculitis 30.7 IFNA2 MEFV TNF
10 arthritis 30.7 CXCL8 PSTPIP1 TNF
11 erysipelas 30.6 MEFV TNF
12 pouchitis 30.5 CXCL8 NOD2
13 polyarteritis nodosa 30.4 IFNA2 MEFV
14 wegener granulomatosis 30.2 CXCL8 ITGB2 TNF
15 prostatitis 29.8 CXCL8 TNF
16 acute respiratory distress syndrome 29.7 CXCL8 TNF
17 mooren's ulcer 29.5 ITGB2 NLRP3
18 aphthous stomatitis 29.2 MEFV NLRP3 TNF
19 pyoderma 28.2 CXCL8 IFNA2 ITGB2 MEFV MMP10 NOD2
20 pyogenic arthritis, pyoderma gangrenosum and acne 12.7
21 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 12.5
22 pyoderma gangrenosum-acne-suppurative hidradenitis syndrome 12.3
23 crohn's disease 11.6
24 corticosteroid-sensitive aseptic abscesses 11.5
25 polydactyly, postaxial, type a1 11.2
26 sweat gland disease 10.7 PSTPIP1 TNF
27 systemic onset juvenile idiopathic arthritis 10.7 MEFV TNF
28 autoinflammation, panniculitis, and dermatosis syndrome 10.7 MEFV TNF
29 granulomatous dermatitis 10.6 NOD2 TNF
30 tungiasis 10.6 CXCL8 TNF
31 streptococcal toxic-shock syndrome 10.6 CXCL8 TNF
32 inflammatory bowel disease 3 10.6 NOD2 TNF
33 orofacial granulomatosis 10.5 NOD2 TNF
34 streptococcal meningitis 10.5 NOD2 TNF
35 trichuriasis 10.5 CXCL8 TNF
36 haemophilus influenzae 10.5 CXCL8 TNF
37 sebaceous gland disease 10.5 CXCL8 PSTPIP1
38 clonorchiasis 10.5 CXCL8 TNF
39 meconium aspiration syndrome 10.5 CXCL8 TNF
40 louse-borne relapsing fever 10.5 CXCL8 TNF
41 dental pulp disease 10.5 CXCL8 TNF
42 transverse myelitis 10.5 CXCL8 TNF
43 adult-onset still's disease 10.5 MEFV TNF
44 pleural tuberculosis 10.5 CXCL8 TNF
45 inflammatory bowel disease 10.5
46 tuberculous meningitis 10.5 CXCL8 TNF
47 q fever 10.4 NOD2 TNF
48 cytomegalovirus infection 10.4 CXCL8 TNF
49 pulpitis 10.4 CXCL8 TNF
50 pharyngitis 10.4 CXCL8 MEFV

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:



Diseases related to Pyoderma Gangrenosum

Symptoms & Phenotypes for Pyoderma Gangrenosum

Human phenotypes related to Pyoderma Gangrenosum:

59 32 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 atrophic scars 59 32 frequent (33%) Frequent (79-30%) HP:0001075
2 rheumatoid arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001370
3 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
4 inflammation of the large intestine 59 32 frequent (33%) Frequent (79-30%) HP:0002037
5 arthralgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002829
6 myelodysplasia 59 32 frequent (33%) Frequent (79-30%) HP:0002863
7 myalgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003326
8 abnormal blistering of the skin 59 32 occasional (7.5%) Occasional (29-5%) HP:0008066
9 increased antibody level in blood 59 32 frequent (33%) Frequent (79-30%) HP:0010702
10 myeloid leukemia 59 32 frequent (33%) Frequent (79-30%) HP:0012324
11 myositis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100614
12 papule 59 32 hallmark (90%) Very frequent (99-80%) HP:0200034
13 skin vesicle 59 32 occasional (7.5%) Occasional (29-5%) HP:0200037
14 pustule 59 32 frequent (33%) Frequent (79-30%) HP:0200039
15 skin ulcer 59 32 hallmark (90%) Very frequent (99-80%) HP:0200042

MGI Mouse Phenotypes related to Pyoderma Gangrenosum:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.17 ITGB2 MEFV MMP10 NLRP3 NOD2 PSTPIP1

Drugs & Therapeutics for Pyoderma Gangrenosum

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4,Not Applicable 170277-31-3
2 Gastrointestinal Agents Phase 4,Not Applicable
3 Dermatologic Agents Phase 4,Phase 2,Not Applicable
4 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
5
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
6
Adalimumab Approved Phase 2, Phase 3,Phase 3 331731-18-1 16219006
7
Azathioprine Approved Phase 3 446-86-6 2265
8
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
9 Anti-Bacterial Agents Phase 3
10 Anti-Infective Agents Phase 3
11 Mesalamine Phase 3,Phase 2 89-57-6
12 Analgesics Phase 3
13 glucocorticoids Phase 3
14 Analgesics, Non-Narcotic Phase 3
15 N-Methylaspartate Phase 3
16 Hormone Antagonists Phase 3
17 Hormones Phase 3
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
19 Peripheral Nervous System Agents Phase 3
20 Pharmaceutical Solutions Phase 3,Phase 2
21 Immunosuppressive Agents Phase 3,Phase 2
22 Liver Extracts Phase 3
23 Anti-Inflammatory Agents Phase 3,Phase 2
24 Anti-Inflammatory Agents, Non-Steroidal Phase 3
25 Antimetabolites Phase 3
26 Antimetabolites, Antineoplastic Phase 3
27 Antineoplastic Agents, Hormonal Phase 3
28 alanine Nutraceutical Phase 3
29 Aspartic Acid Nutraceutical Phase 3
30
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
31 Antibodies Phase 2,Phase 1
32 Immunoglobulins Phase 2,Phase 1
33 Antibodies, Monoclonal Phase 2,Phase 1
34 Calcineurin Inhibitors Phase 2
35
Certolizumab pegol Approved 428863-50-7
36 Vedolizumab Approved 943609-66-3

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery Completed NCT00688636 Phase 4 infliximab;placebo
2 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
3 A Comparison of Once a Day Dose Compared to 2 Doses/Day Completed NCT00505778 Phase 3 Mesalamine Once-Daily;Mesalamine Twice-Daily
4 A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease Completed NCT00445432 Phase 2, Phase 3
5 Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease Completed NCT01235689 Phase 3 Prednisone;Azathioprine
6 A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan Recruiting NCT03311464 Phase 3 adalimumab
7 An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02326740 Phase 3 gevokizumab;Placebo;gevokizumab open-label
8 An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02315417 Phase 3 gevokizumab;Placebo;gevokizumab open-label
9 A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum Terminated NCT02318914 Phase 3 gevokizumab
10 Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum Completed NCT01882504 Phase 2 gevokizumab
11 A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Completed NCT01965613 Phase 2
12 Canakinumab for Pyoderma Gangrenosum Completed NCT01302795 Phase 2 Canakinumab
13 Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease Completed NCT01233570 Phase 2 Tacrolimus
14 Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis Completed NCT01036022 Phase 2 GSK1399686
15 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Recruiting NCT03137160 Phase 2
16 Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Recruiting NCT02733094 Phase 1, Phase 2 Secukinumab
17 Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum Recruiting NCT03072953 Phase 2 APD334
18 Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum Withdrawn NCT00730717 Phase 2 Humira;Humira
19 Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Withdrawn NCT00690846 Phase 2 adalimumab
20 Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease Completed NCT00791557 Not Applicable Infliximab
21 Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors Completed NCT00933296
22 Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases Recruiting NCT01952275
23 Entyvio (Vedolizumab) Long Term Safety Study Recruiting NCT02674308 Vedolizumab
24 Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease Recruiting NCT03495973 Ustekinumab
25 Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) Terminated NCT01577264

Search NIH Clinical Center for Pyoderma Gangrenosum

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: pyoderma gangrenosum

Genetic Tests for Pyoderma Gangrenosum

Anatomical Context for Pyoderma Gangrenosum

MalaCards organs/tissues related to Pyoderma Gangrenosum:

41
Skin, Neutrophil, Lung, T Cells, Bone, Myeloid, Liver

Publications for Pyoderma Gangrenosum

Articles related to Pyoderma Gangrenosum:

(show top 50) (show all 781)
# Title Authors Year
1
Pyoderma gangrenosum: a review of pathogenesis and treatment. ( 29406827 )
2018
2
Pyoderma gangrenosum in the genital area: successful treatment using adalimumab. ( 29378677 )
2018
3
A case of chronic ulcer due to subcutaneous arteriolosclerosis in an obese patient mimicking pyoderma gangrenosum. ( 29887980 )
2018
4
Skin Grafting in Pyoderma Gangrenosum. ( 29896322 )
2018
5
The PARACELSUS score: A novel diagnostic tool for pyoderma gangrenosum. ( 29388188 )
2018
6
Pulmonary nodules and nodular scleritis in a teenager with superficial granulomatous pyoderma gangrenosum. ( 29243307 )
2018
7
A Case of Pyoderma Gangrenosum with Myelodysplastic Syndrome. ( 29853768 )
2018
8
Erythema elevatum diutinum associated with severe oropharyngeal ulceration and pyoderma gangrenosum. ( 29750453 )
2018
9
Endovenous Treatment of Varicose Veins in Patients With Pyoderma Gangrenosum. ( 29933301 )
2018
10
Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study. ( 29877043 )
2018
11
Pyoderma Gangrenosum of the Preauricular Area with Ulcerative Colitis: A Case Report and Review. ( 29890815 )
2018
12
Pyoderma gangrenosum with its subtype affecting oral mucosa pyostomatitis vegetans following skin melanoma surgical excision in a patient with ulcerative colitis: a case report. ( 29760625 )
2018
13
A Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe. ( 29854503 )
2018
14
A systematic review of pyoderma gangrenosum with pulmonmary involvement: clinical presentation, diagnosis, and management. ( 29377399 )
2018
15
Pyogenic arthritis pyoderma gangrenosum and acne syndrome: A rare but important diagnosis for antibiotic-resistant erysipelas-like erythema and osteonecrosis. ( 29943877 )
2018
16
Management of Facial Pyoderma Gangrenosum Using Platelet-Rich Fibrin: A Technical Report. ( 29425752 )
2018
17
Case of pyoderma gangrenosum-like sporotrichosis caused by Sporothrix globosa in a patient with ulcerative colitis. ( 29488248 )
2018
18
Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts. ( 29450466 )
2018
19
Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review. ( 29851121 )
2018
20
A case of neutrophilic dermatoses including pyoderma gangrenosum as a continuous disease spectrum to SAPHO syndrome. ( 29756300 )
2018
21
Pyoderma Gangrenosum of the Breast After Mastopexy. ( 29847306 )
2018
22
Cutaneous Diphtheria Mimicking Pyoderma Gangrenosum. ( 29282460 )
2018
23
Successful therapy of Pyoderma gangrenosum with a JAK2 inhibitor. ( 29451690 )
2018
24
Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma. ( 29362816 )
2018
25
A case of pyoderma gangrenosum, acne, hidradenitis suppurativa (PASH) syndrome associated with diabetes mellitus type 1 treated with adalimumab. ( 29368847 )
2018
26
Paraneoplastic Pyoderma Gangrenosum Associated with Rectal Adenocarcinoma. ( 29386837 )
2018
27
The rapidly evolving lesions of ulcerative pyoderma gangrenosum: a timeline. ( 29806128 )
2018
28
Recurrent pyoderma gangrenosum developed after a cesarean section with a 10-year interval. ( 29920658 )
2018
29
<i>LPIN2</i> gene mutation in a patient with overlapping neutrophilic disease (pyoderma gangrenosum and aseptic abscess syndrome). ( 29387759 )
2018
30
The Validity of the Diagnostic Code for Pyoderma Gangrenosum in an Electronic Database. ( 29451671 )
2018
31
Cocaine-induced pyoderma gangrenosum-like lesions. ( 29786948 )
2018
32
Hyperbaric oxygen therapy for pyoderma gangrenosum associated with ulcerative colitis. ( 29422812 )
2018
33
Central retinal arterial occlusion in a patient with pyoderma gangrenosum. ( 29941761 )
2018
34
Two cases of bullous pyoderma gangrenosum complicated by Epstein-Barr virus infection. ( 29952293 )
2018
35
Dental treatment of a rare case of pyoderma gangrenosum with aggressive periodontal disease. ( 29945713 )
2018
36
The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. ( 29438762 )
2018
37
Pyoderma Gangrenosum: A Review for the Gastroenterologist. ( 29788368 )
2018
38
Usefulness of metagenomic analysis in differential diagnosis for pyoderma gangrenosum. ( 29936877 )
2018
39
Pyoderma Gangrenosum Secondary to Severe Congenital Neutropenia. ( 29707446 )
2018
40
Pyoderma gangrenosum-like ulceration of the lower extremity secondary to sunitinib therapy: a case report. ( 29977559 )
2018
41
Cogan's syndrome with pyoderma gangrenosum: management of two uncommon disorders with aggressive presentation in a patient. ( 29925554 )
2018
42
Diagnosis uPGrade-Advances in Pyoderma Gangrenosum. ( 29450448 )
2018
43
The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. ( 29450453 )
2018
44
Suppression of pathergy in pyoderma gangrenosum with infliximab allowing for successful tendon debridement. ( 29379860 )
2018
45
Pyoderma gangrenosum successfully treated with topical tacrolimus. ( 29368849 )
2018
46
Pyoderma gangrenosum affecting the eye, orbit, and adnexa. A review. ( 28862478 )
2017
47
Pyoderma gangrenosum-like ulcer caused by Helicobacter cinaedi in a patient with hypogammaglobulinemia. ( 28815770 )
2017
48
Pyoderma gangrenosum in a patient with chronic granulomatous disease: A case report. ( 28767612 )
2017
49
Pyoderma Gangrenosum: A Current Problem as Much as an Unknown One. ( 28915774 )
2017
50
Topical Medical Cannabis (TMC): A new treatment for wound pain-Three cases of Pyoderma Gangrenosum. ( 28818631 )
2017

Variations for Pyoderma Gangrenosum

Expression for Pyoderma Gangrenosum

Search GEO for disease gene expression data for Pyoderma Gangrenosum.

Pathways for Pyoderma Gangrenosum

Pathways related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 CXCL8 IFNA2 ITGB2 MEFV NLRP3 NOD2
2
Show member pathways
13.08 CXCL8 IFNA2 ITGB2 NOD2 TNF
3
Show member pathways
12.63 CXCL8 IFNA2 ITGB2 TNF
4
Show member pathways
12.53 CXCL8 IFNA2 NLRP3 TNF
5
Show member pathways
12.02 CXCL8 IFNA2 MEFV NLRP3 NOD2 PSTPIP1
6
Show member pathways
11.97 IFNA2 NLRP3 TNF
7 11.88 IFNA2 ITGB2 NOD2 TNF
8 11.8 CXCL8 IFNA2 TNF
9 11.71 CXCL8 ITGB2 TNF
10 11.62 CXCL8 ITGB2 TNF
11 11.56 CXCL8 ITGB2 TNF
12
Show member pathways
11.52 MEFV NLRP3 NOD2 PSTPIP1
13 11.32 CXCL8 ITGB2 TNF
14 11.23 CXCL8 ITGB2 TNF
15 11.14 CXCL8 ITGB2 NLRP3 TNF
16 11.05 MEFV NLRP3 NOD2
17 10.95 CXCL8 TNF
18 10.91 NOD2 TNF
19 10.8 CXCL8 TNF

GO Terms for Pyoderma Gangrenosum

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.86 MEFV NLRP3 NOD2 PSTPIP1
2 innate immune response GO:0045087 9.85 IFNA2 MEFV NLRP3 NOD2 PSTPIP1
3 cytokine-mediated signaling pathway GO:0019221 9.83 CXCL8 IFNA2 ITGB2 TNF
4 cellular response to lipopolysaccharide GO:0071222 9.71 CXCL8 NLRP3 TNF
5 regulation of inflammatory response GO:0050727 9.69 NLRP3 NOD2 TNF
6 receptor internalization GO:0031623 9.61 CXCL8 ITGB2
7 positive regulation of nitric oxide biosynthetic process GO:0045429 9.6 ITGB2 TNF
8 signaling GO:0023052 9.59 NLRP3 NOD2
9 negative regulation of immune response GO:0050777 9.58 NLRP3 NOD2
10 positive regulation of interleukin-8 production GO:0032757 9.58 NOD2 TNF
11 positive regulation of interleukin-1 beta secretion GO:0050718 9.57 NLRP3 NOD2
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.56 ITGB2 NLRP3 NOD2 TNF
13 embryonic digestive tract development GO:0048566 9.55 CXCL8 TNF
14 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.5 NLRP3 NOD2 TNF
15 positive regulation of type 2 immune response GO:0002830 9.49 NLRP3 NOD2
16 cellular response to peptidoglycan GO:0071224 9.48 NLRP3 NOD2
17 negative regulation of inflammatory response GO:0050728 9.46 MEFV MVK NLRP3 NOD2
18 cellular extravasation GO:0045123 9.43 ITGB2 TNF
19 detection of biotic stimulus GO:0009595 9.4 NLRP3 NOD2
20 cytokine secretion involved in immune response GO:0002374 9.37 NLRP3 NOD2
21 defense response GO:0006952 9.35 CXCL8 IFNA2 NLRP3 NOD2 TNF
22 inflammatory response GO:0006954 9.23 CXCL8 IFNA2 ITGB2 MEFV NLRP3 NOD2

Molecular functions related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.35 MEFV MVK NLRP3 PSTPIP1 TNF
2 cytokine activity GO:0005125 9.33 CXCL8 IFNA2 TNF
3 peptidoglycan binding GO:0042834 8.62 NLRP3 NOD2

Sources for Pyoderma Gangrenosum

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....